Albireo Pharma Inc

Albireo Pharma — Biodel — Technical Presentation (March 2015)

12 slides from Albireo Pharma's technical presentation, Mar 16, 2015

  1. Slide 1: Study 6-101 Phase 1 Trial: Preliminary Results

    Study 6-101 Phase 1 Trial: Preliminary Results Biodel’s Glucagon Formulation For Use in a Proprietary Auto-Reconstitution Device For the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint Monday March 16, 8:30 a.m. EDT HSBIoDEL Life Delivered®

  2. Slide 2: Phase 1 Study 6-101 Trial Design and Objectives

    | By) Phase 1 Study 6-101 Trial Design and Objectives Single center, double blind, randomized six-period crossover study to evaluate the PK, PD and safety profiles of, BIOD.961 (lyophilized glucagon formulation designed for use in GEM auto-reconstitution device) vs. glucagon formulations marketed by

  3. Slide 3: BIOD-961 Shows Similar PK and PD Profiles to Lilly and Novo Glucagons Following IM Injection

    pe) BIOD-961 Shows Similar Pharmacokinetic and Pharmacodynamic Profiles to Lilly and Novo Glucagons Following Intramuscular (IM) Injection 10 195 3 2 8100-961 (1 me iM) 180 + 8100-961 (2 mg im) ge uy ime Z ies =u cme) 37 mettre Bis revetment gs 135 ‘a 8 20 co ¥ © 105 ee 8 g2 3” 2; 75 0 0 0 30 6 9 12

  4. Slide 4: Bioequivalence Criteria Assessments of BIOD-961 vs. Lilly and Novo Glucagons Following IM Injection

    pl Bioequivalence Criteria Assessments of BIOD-961 vs. Lilly and Novo Glucagons Following Intramuscular (IM) Injection Pharmacodynamic Pharmacokinetic Ratio (90% Confidence Interval) Novo Glucagon IM 1.06 (0.99-1.13)* 1.03 (0.98-1.07)* Test vs. Reference BG BG AUC g240min co AUC o.240min BIOD-961 IM

  5. Slide 5: BIOD-961 Shows Similar PK and PD Profiles to Lilly and Novo Glucagons Following SC Injection

    aS 200 600 o BBIODEL Plasma Glucagon (ug/L) 2 1100-961 amesc) ety (me sc) me Nove mgs) 0 30 60 9 120 150 180 210 240 me From dost mi AUC 0.240 min Conus (ug*min/L) b (pe/Y) aig - 8 6 4 2 ° 00-961 uly Nov 100-961 uly Nove BIOD-961 Shows Similar Pharmacokinetic and Pharmacodynamic Profiles to Lilly an

  6. Slide 6: Bioequivalence Criteria Assessments of BIOD-961 vs. Lilly and Novo Glucagons Following SC Injection

    | 5 Bioequivalence Criteria Assessments of BIOD-961 vs. Lilly and Novo Glucagons Following Subcutaneous (SC) Injection Test vs. Reference Pharmacodynamic Pharmacokinetic Ratio (90% Confidence Interval) BG rae BG AUC o.240min onwx AUC 6200 min BIOD-961 SC vs. 4 -1,06)* ¥ ie cured 1.02 (0.94-1.09)* |

  7. Slide 7: Comparison of Pharmacokinetic Profiles of BIOD-961 to Published Pivotal Lilly Glucagon Bioequivalence Data

    Comparison of Pharmacokinetic Profiles of BIOD-961 to Published Pivotal Lilly Glucagon Bioequivalence Data ‘SC Administration . IMAdministration Graf etat J Pharm ny ‘Sei: 8: 901-008, 1000 7 oe 7 acetic od BIOD-961 ‘2, BIOD-961 3 Bn rt E38 8 8 z ef B2 B2 0 0 o 1 223 4 o 1 2 3 Time, hours from dosing

  8. Slide 8: Comparison of Pharmacokinetic Parameters to Lilly Glucagon: BIOD-961 vs. Xeris GlucaPen Formulation

    py Comparison of Pharmacokinetic Parameters to Lilly Glucagon Following Subcutaneous Injection: BIOD-961 vs. Xeris GlucaPen Formulation BIOD-961 AUC oe Coe Toa 600 (ug*min/t) 10 (ue/t) 40 (nin) 9 550 3 = 7 30 300 a 450 5 2s 4 400 3 20 2 15 350 2 300 0 10 Lily 21mg 8100-961 1 mg Lilly 1 mg BIOD-961.1

  9. Slide 9: Study 6-101 Phase 1 Trial: Preliminary Results

    Study 6-101 Phase 1 Trial: Preliminary Results Biodel’s Glucagon Formulation For Use in a Proprietary Auto-Reconstitution Device For the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint Monday March 16, 8:30 a.m. EDT BOSBIoDEL Life Delivered®

  10. Slide 10: Majority of Patients and Caregivers View GEM as Substantially Better Than Currently Available Glucagon Kits

    a Majority of Patients and Caregivers View GEM as Being Yj Substantially Better Than the Currently Available Glucagon Kits Patient/Caregiver Feedback atient/Caregiver intial Reaction to GEM (Product X) as Compared to Current Perception of Options: GEM (Product X) ae a3) Valve: High = Substantial bet

  11. Slide 11: In an Upside Scenario, Net 2025 Revenues of ~$435M Can Be Realized By the GEM Device

    my In an Upside Scenario, Net 2025 Revenues of is ~$435M Can Be Realized By the GEM Device U.S. Net Revenue Upside Case Revenues BIODEL GEM DEVICE U.S. NET REVENUE FORECAST ‘Significant market development to support: = Growth in prescription of glucagon — Growth in refills after expiry — Growth in u

  12. Slide 12: Study 6-101 Phase 1 Trial: Preliminary Results

    Study 6-101 Phase 1 Trial: Preliminary Results Biodel’s Glucagon Formulation For Use in a Proprietary Auto-Reconstitution Device For the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint Monday March 16, 8:30 a.m. EDT HABIODEL Life Delivered®

Biodel — Technical Presentation (March 2015) on 6ix